Loss of wild-type p53 promotes mutant p53-driven metastasis through acquisition of survival and tumor-initiating properties

被引:36
作者
Nakayama, Mizuho [1 ,2 ]
Hong, Chang Pyo [3 ]
Oshima, Hiroko [1 ,2 ]
Sakai, Eri [1 ]
Kim, Seong-Jin [3 ,4 ,5 ]
Oshima, Masanobu [1 ,2 ]
机构
[1] Kanazawa Univ, Canc Res Inst, Div Genet, Kanazawa, Ishikawa 9201192, Japan
[2] Kanazawa Univ, WPI Nano Life Sci Inst, Kanazawa, Ishikawa 9201192, Japan
[3] Theragen Etex Bio Inst, Suwon 16229, South Korea
[4] Seoul Natl Univ, Precis Med Res Ctr, Adv Inst Convergence Technol, Suwon 16229, South Korea
[5] Seoul Natl Univ, Dept Transdisciplinary Studies, Suwon 16229, South Korea
关键词
DRIVES METASTASIS; CANCER; GAIN; GENE; COMPLEX; CELLS; PATTERNS; MUTATION; GROWTH;
D O I
10.1038/s41467-020-16245-1
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Missense-type mutant p53 plays a tumor-promoting role through gain-of-function (GOF) mechanism. In addition, the loss of wild-type TP53 through loss of heterozygosity (LOH) is widely found in cancer cells. However, malignant progression induced by cooperation of TP53 GOF mutation and LOH remains poorly understood. Here, we show that mouse intestinal tumors carrying Trp53 GOF mutation with LOH (AKTP(M/LOH)) are enriched in metastatic lesions when heterozygous Trp53 mutant cells (AKTP(+/M)) are transplanted. We show that Trp53 LOH is required for dormant cell survival and clonal expansion of cancer cells. Moreover, AKTP(M/LOH) cells show an increased in vivo tumor-initiating ability compared with AKTP(Null) and AKTP(+/M) cells. RNAseq analyses reveal that inflammatory and growth factor/MAPK pathways are specifically activated in AKTP(M/LOH) cells, while the stem cell signature is upregulated in both AKTP(M/LOH) and AKTP(Null) cells. These results indicate that TP53/Trp53 LOH promotes TP53/Trp53 GOF mutation-driven metastasis through the activation of distinct pathway combination. Both gain-of-function of mutant p53 (GOF) and loss of wild-type p53 (LOH) are independently associated with cancer. Here, the authors show that LOH promotes GOF tumourigenesis by increasing tumor-initiating ability and metastasis.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] FUCAI is induced by wild-type p53 and expressed at different levels in thyroid cancers depending on p53 status
    Tsuchida, Nobuo
    Ikeda, Masa-Aki
    Ishino, Yoshizumu
    Grieco, Michele
    Vecchio, Giancarlo
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2017, 50 (06) : 2043 - 2048
  • [32] Re-oxygenation causes hypoxic tumor regression through restoration of p53 wild-type conformation and post-translational modifications
    Gogna, R.
    Madan, E.
    Kuppusamy, P.
    Pati, U.
    CELL DEATH & DISEASE, 2012, 3 : e286 - e286
  • [33] Editorial: Advances in wild type and mutant p53 research in cancer
    Hernandez-de la Cruz, Olga N.
    Dominguez-Gomez, Guadalupe
    Deb, Moonmoon
    Diaz-Chavez, Jose
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2022, 9
  • [34] SLMP53-1 interacts with wild-type and mutant p53 DNA-binding domain and reactivates multiple hotspot mutations
    Gomes, Ana Sara
    Ramos, Helena
    Gomes, Sara
    Loureiro, Joana B.
    Soares, Joana
    Barcherini, Valentina
    Monti, Paola
    Fronza, Gilberto
    Oliveira, Carla
    Domingues, Lucilia
    Bastos, Margarida
    Dourado, Daniel F. A. R.
    Carvalho, Ana Luisa
    Romao, Maria Joao
    Pinheiro, Benedita
    Marcelo, Filipa
    Carvalho, Alexandra
    Santos, Maria M. M.
    Saraiva, Lucilia
    BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2020, 1864 (01):
  • [35] High-Level Expression of Wild-Type p53 in Melanoma Cells is Frequently Associated with Inactivity in p53 Reporter Gene Assays
    Houben, Roland
    Hesbacher, Sonja
    Schmid, Corinna P.
    Kauczok, Claudia S.
    Flohr, Ulrike
    Haferkamp, Sebastian
    Mueller, Cornelia S. L.
    Schrama, David
    Wischhusen, Joerg
    Becker, Juergen C.
    PLOS ONE, 2011, 6 (07):
  • [36] Mutant p53 controls tumor metabolism and metastasis by regulating PGC-1α
    Basu, Subhasree
    Gnanapradeepan, Keerthana
    Barnoud, Thibaut
    Kung, Che-Pei
    Tavecchio, Michele
    Scott, Jeremy
    Watters, Andrea
    Chen, Qing
    Kossenkov, Andrew V.
    Murphy, Maureen E.
    GENES & DEVELOPMENT, 2018, 32 (3-4) : 230 - 243
  • [37] Targeting Mdmx to treat breast cancers with wild-type p53
    Haupt, S.
    Buckley, D.
    Pang, J-M B.
    Panimaya, J.
    Paul, P. J.
    Gamell, C.
    Takano, E. A.
    Lee, Y. Ying
    Hiddingh, S.
    Rogers, T-M
    Teunisse, A. F. A. S.
    Herold, M. J.
    Marine, J-C
    Fox, S. B.
    Jochemsen, A.
    Haupt, Y.
    CELL DEATH & DISEASE, 2015, 6 : e1821 - e1821
  • [38] Nrf2 promotes mutant K-ras/p53-driven pancreatic carcinogenesis
    Hamada, Shin
    Taguchi, Keiko
    Masamune, Atsushi
    Yamamoto, Masayuki
    Shimosegawa, Tooru
    CARCINOGENESIS, 2017, 38 (06) : 661 - 670
  • [39] Pharmacological activation of tumor suppressor, wild-type p53 as a promising strategy to fight cancer
    Sznarkowska, Alicja
    Olszewski, Robert
    Zawacka-Pankau, Joanna
    POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, 2010, 64 : 396 - 407
  • [40] Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene
    Lang, FF
    Yung, WKA
    Raju, U
    Libunao, F
    Terry, NHA
    Tofilon, PJ
    JOURNAL OF NEUROSURGERY, 1998, 89 (01) : 125 - 132